Thalidomide: days Immunomodulator therapy (IMiD e.g. lenalidomide or thalidomide) - week History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide Prior treatment with lenalidomide; patients previously treated with thalidomide who discontinued treatment for reasons aside from an adverse reaction to thalidomide are permitted Known hypersensitivity to thalidomide or lenalidomide Known hypersensitivity to thalidomide. Patients who experienced thromboembolic events while on full anticoagulation during prior therapy with lenalidomide or thalidomide. Any prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have allergic reactions or other \significant toxicity\ per Investigator discretion associated with lenalidomide or thalidomide use. Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs) History of grade rash associated with thalidomide treatment Known hypersensitivity to lenalidomide or thalidomide, ibrutinib, rituximab, etoposide, vincristine,\r\ndoxorubicin, cyclophosphamide, or prednisone History of hypersensitivity of lenalidomide or thalidomide Patients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide) Lenalidomide, thalidomide and pomalidomide Known hypersensitivity to thalidomide or lenalidomide Known hypersensitivity to thalidomide, lenalidomide or ipilimumab Known hypersensitivity to thalidomide Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide Known hypersensitivity to thalidomide Known hypersensitivity to thalidomide or lenalidomide Known hypersensitivity to thalidomide. Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide Hypersensitivity to thalidomide, lenalidomide, pomalidomide, bortezomib, or dexamethasone (such as Stevens-Johnson syndrome); rash to immunomodulatory drug that can be medically managed is allowable History of erythema multiforme or severe hypersensitivity to prior IMiDs such as thalidomide and lenalidomide Had rash ? Grade during prior thalidomide, lenalidomide, or pomalidomide therapy Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dex Prior thalidomide is allowed, however, patients must not have prior >= grade- allergic reactions to thalidomide History of erythema multiforme, Grade >= rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomide Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone Known hypersensitivity to thalidomide For MM- cohort only: Hypersensitivity (eg, Rash Grade or ) to thalidomide, lenalidomide, or dexamethasone (MM-b). Known hypersensitivity to thalidomide or rituximab Hypersensitivity to IMiDs (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the first cycles or toxicity, which does meet intolerance definition. Arm A only: ImiDs (eg, lenalidomide, thalidomide); Prior therapy with thalidomide in combination with ruxolitinib Known hypersensitivity to thalidomide or lenalidomide Patients with a prior history of serious allergic reactions associated with thalidomide or lenalidomide Patients who have received pomalidomide in the past are not eligible; patients who have prior treatment with other immunomodulatory drugs (IMiDs) (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have \significant toxicity\ associated with lenalidomide or thalidomide use; a significant toxicity will be defined as one that required a dose reduction or discontinuation due to toxicity; please discuss any questions with the PI Known hypersensitivity to thalidomide Known hypersensitivity to thalidomide or lenalidomide Known hypersensitivity to thalidomide or lenalidomide Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for treatment of MDS or myeloproliferative neoplasm (MPN) (e.g. azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors, hematopoietic growth factors, interferon, lenalidomide, thalidomide) will be eligible for this trial as long as immunomodulatory drugs (e.g. lenalidomide, thalidomide) have not been used in the past months Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable Hypersensitivity to previous lenalidomide or thalidomide Known hypersensitivity to thalidomide Patients with a prior history of grade rash associated with thalidomide treatment Hypersensitivity to thalidomide, lenalidomide or pomalidomide Known hypersensitivity to thalidomide or lenalidomide (if applicable) Known hypersensitivity to thalidomide or lenalidomide. Known hypersensitivity to thalidomide or lenalidomide Known hypersensitivity to thalidomide Known hypersensitivity to thalidomide. Known hypersensitivity to thalidomide or lenalidomide. Prior therapy with thalidomide and lenalidomide is allowed Patient has known hypersensitivity to thalidomide Known hypersensitivity to thalidomide Must have received at least one () prior line of systemic treatment that has included either lenalidomide or thalidomide. Known hypersensitivity to thalidomide Known hypersensitivity to thalidomide or lenalidomide (if applicable) Grade rash due to prior thalidomide treatment Have known hypersensitivity to thalidomide or lenalidomide Patients with known hypersensitivity to thalidomide or lenalidomide or pomalidomide Known hypersensitivity to thalidomide or lenalidomide Patients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomide History of hypersensitivity to IMiDs (lenalidomide, pomalidomide, thalidomide). Known hypersensitivity to thalidomide or other immunomodulatory drugs. Known hypersensitivity to thalidomide or lenalidomide (if applicable) Known hypersensitivity to thalidomide or Revlimid (if applicable) Known hypersensitivity to thalidomide or lenalidomide Known history of resistance to thalidomide Lenalidomide, thalidomide and pomalidomide Subjects must have received prior treatment with bortezomib, and either thalidomide or lenalidomide Known hypersensitivity to lenalidomide or thalidomide Known hypersensitivity to thalidomide Hypersensitivity to thalidomide, lenalidomide, or dexamethasone Prior Therapy with thalidomide, lenalidomide or pomalidomide Known hypersensitivity to thalidomide or lenalidomide (if applicable) Known hypersensitivity to thalidomide or lenalidomide Known sensitivity to lenalidomide or other thalidomide derivatives